Have to say that is a very poor week. We are getting outperformed by a generic (i.e no sales force at all and probably not much marketing) which is also a generic of an inferior product.
One dot in a series I know but we should be smashing this out of the park. Yes,we are doing well, but not exceptionally well.
... and we have an exceptional drug.
Whilst in favour of a BO in 2019 I had been somewhat ambivalent. Looking at the long road ahead for GIA together with the sales/marketing and PR of AMRN, an the ignorance of vast swathes of the medical profession- not any more.
Thank you Sam. I must admit that I look forward to seeing the numbers you provide albeit with trepidation now. We no longer have the first quarter to use as a reason for not seeing the hockey stick in sales. We did not have a short week, spring break is over, the sales force has been in the field and contacted the target physicians multiple times. I now believe that we will not see a serious ramp up in sales until after FDA approval and direct to consumer advertising begins. I also find the lack of a European submission very puzzling. We know that we are dealing with a limited time of exclusivity. Every day that Amarin does not submit a European application diminishes the value to shareholders.
News 
Market Data 
Discover 
